Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
about
sameAs
Coccidioidomycosis--a fungal disease of the AmericasVoriconazole versus amphotericin B or fluconazole in cancer patients with neutropeniaAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsAntifungal therapy in infants and children with proven, probable or suspected invasive fungal infectionsVoriconazole versus amphotericin B in cancer patients with neutropeniaNovel perspectives on mucormycosis: pathophysiology, presentation, and management.Voriconazole therapeutic drug monitoring.Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome.Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotationsFungal infections of the orbitModulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic TargetOptimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal DiseasesInvasive mold infections in solid organ transplant recipientsRecommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Pneumonia in the neutropenic cancer patientHow to manage aspergillosis in non-neutropenic intensive care unit patientsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectivePharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsAcetazolamide-based fungal chitinase inhibitorsStructure of N-myristoyltransferase from Aspergillus fumigatusAnti-Immune Strategies of Pathogenic FungiAntifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsFundament and Prerequisites for the Application of an Antifungal TDM ServiceComparison of echinocandin antifungalsTreatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Invasive aspergillosis in the intensive care unitHsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurinGenetic variation in plant CYP51s confers resistance against voriconazole, a novel inhibitor of brassinosteroid-dependent sterol biosynthesisDiscovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossingUtilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.SVoriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosisCombination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosisPosaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other ConditionsEpidemiology of invasive candidiasis: a persistent public health problemA computational model of invasive aspergillosis in the lung and the role of iron.Aspergillus infections in transplant and non-transplant surgical patientsFatal clinical course of probable invasive pulmonary aspergillosis with influenza B infection in an immunocompetent patient.Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortalityAspergillus endocarditis: a case of near complete left ventricular outflow obstruction.
P2860
Q21144726-0ABF7E3A-8660-4DB2-9F55-C6E68FFF72B9Q24200304-1C80D00F-529A-43BC-AC20-56CE6E448BDAQ24239978-5B0361A9-093B-47BD-9B9D-1C0953268430Q24243629-9D783D20-6B91-4A54-9DB3-F7A5D9B39AF3Q24244950-AF4974DC-372B-4179-B76D-727BAFFF7E9DQ24530554-4D1F67D5-F946-4888-8319-959EECAD2E2EQ24542411-CCF6EDB2-0BFA-47C6-9019-6BABB77E7B4CQ24811601-1EE321E5-97E1-4153-BF1F-0CADCEDEA342Q25257632-DB90B955-23DA-458D-8F03-6D90BCCDC063Q26744426-460229BB-32AA-4015-9B58-76CFA383F329Q26748251-AB767809-5584-45CF-BA64-305E8684E274Q26774692-82D4B5D6-B95F-4F00-A71A-3A01BCE894C4Q26823811-687F3DB8-8D9D-4AA4-AE84-4CAAC9AFFA36Q26824260-E571FC5B-4BC1-41BF-9EC9-808457C6F1FEQ26827758-74FD24D6-9433-493E-84DA-64E1ACD93F11Q26999448-4EA4BB32-018E-47E2-998B-5A3C28FCA39FQ27009221-97F8114D-F13A-4A20-BD54-F479F5556B0CQ27025299-6E5C9645-02D3-4991-B215-779193F30283Q27665555-1D2147A8-ABE9-404E-8D65-1F3262FD2D19Q27700103-05198A93-C359-453F-A642-E4DF1D68963FQ28071716-A8359C27-B946-4D5D-AEE3-49B2522B7005Q28080147-AE508793-20CB-4C5F-A1A5-BF74EB1B62E2Q28085352-653E80D0-DA04-48FE-A8E0-A9B0D4AF66BCQ28273738-D59D6FEC-12C3-4891-B16F-76B4AEAA3AFAQ28277029-A5763110-7D84-4C1E-AAFC-FB9E7A1CE7B9Q28298468-9C5C3F4E-7DDB-4FC3-8C61-7BE3832E1EFCQ28306909-571C5715-E497-4DBA-8D14-72B19950847FQ28475818-F72A599A-70AC-4B26-B8D3-BD1243C3C734Q28485119-6A47FBA8-213C-46CD-B25F-FE7F3345E297Q28485433-C0563709-4EB9-4D91-A518-2B1BAD51CCB6Q28538618-ED5ED8FD-EFA3-4419-A14A-DBE6E7AFC8DDQ28540254-A65EDA33-CC60-4FD9-BA7C-68D466536526Q28727508-5A73FE8C-68C0-4413-8105-F04660459CB5Q29399166-6BAD4307-3069-4B9E-BA26-26838925558DQ29616758-5B6999B8-4416-4766-A14C-7C95CF3B5D22Q30276951-D66A3AE1-0DAA-4CBF-B848-0C9296990C70Q30361624-36582F73-A2B4-446C-91F8-9B8C1D899433Q30367762-6FE7C656-AFEC-4BF0-9744-1090E9B5277DQ30438524-E1EC575C-B09B-46F4-A795-D505BE9AAC6CQ30514075-DDA64381-0B21-4DF0-83E9-629E2A8F231B
P2860
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@ast
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@en
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@nl
type
label
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@ast
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@en
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@nl
prefLabel
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@ast
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@en
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@nl
P2093
P50
P3181
P356
P1476
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
@en
P2093
Ben de Pauw
Christine Durand
Denis Caillot
Eckhard Thiel
Haran T Schlamm
John E Bennett
John R Wingard
Jörg-W Oestmann
Kieren A Marr
Michael R Hodges
P304
P3181
P356
10.1056/NEJMOA020191
P407
P577
2002-08-08T00:00:00Z